Drug Profile
KL 1333
Alternative Names: KL 1333D; KL 1333M; KL1333Latest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator KT&G Life Sciences
- Developer Abliva; Yungjin Pharm Co
- Class Small molecules
- Mechanism of Action Nicotinamide adenine dinucleotide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Mitochondrial disorders
- No development reported Diabetes mellitus
Most Recent Events
- 02 Jan 2024 KL 1333 receives Fast track status from the US FDA for Mitochondrial disorders (Abliva pipeline, January 2024)
- 27 Jan 2023 Phase-II/III clinical trials in Mitochondrial disorders (In adults, In the elderly) in United Kingdom (PO) (NCT05650229) (EudraCT2021-002846-33)
- 13 Oct 2022 Phase-II/III clinical trials in Mitochondrial disorders (In adults, In the elderly) in Denmark (PO) (EudraCT2021-002846-33)